Growth Metrics

Pfizer (PFE) Cash from Investing Activities (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 112.77%
Dec 31, 2025 -152.92%
Sep 28, 2025 -161.50%
Jun 29, 2025 20.68%
Sep 29, 2024 -7.07%
Jun 30, 2024 165.59%
Mar 31, 2024 115.75%
Dec 31, 2023 -1,338.29%
Oct 1, 2023 103.48%
Jul 2, 2023 -868.78%
Oct 2, 2022 -0.53%
Jul 3, 2022 -2,095.24%
Oct 3, 2021 -145.19%
Jul 4, 2021 -365.77%
Sep 27, 2020 3.15%
Jun 28, 2020 -18,225.35%
Mar 29, 2020 97.49%
Dec 31, 2019 58.09%
Sep 29, 2019 -255.42%
Jun 30, 2019 -125.19%
Mar 31, 2019 1,170.92%
Dec 31, 2018 75.72%
Sep 30, 2018 -97.01%
Jul 1, 2018 -115.25%
Apr 1, 2018 303.13%
Dec 31, 2017 -58.05%
Oct 1, 2017 -73.25%
Jul 2, 2017 -136.45%
Apr 2, 2017 254.45%
Dec 31, 2016 29.54%
Oct 2, 2016 6.35%
Jul 3, 2016 -207.42%
Apr 3, 2016 295.82%
Dec 31, 2015 57.58%
Sep 27, 2015 -149.07%
Jun 28, 2015 -131.93%
Mar 29, 2015 535.40%
Dec 31, 2014 40.28%
Sep 28, 2014 -68.21%
Jun 29, 2014 -1,437.76%
Mar 30, 2014 -169.01%
Dec 31, 2013 123.55%
Sep 29, 2013 -171.53%
Jun 30, 2013 107.72%
Mar 31, 2013 -259.81%
Dec 31, 2012 2,868.02%
Sep 30, 2012 72.15%
Jul 1, 2012 -296.67%
Apr 1, 2012 -16.79%
Dec 31, 2011 152.09%
Oct 2, 2011 -40.44%
Jul 3, 2011 -50.21%
Apr 3, 2011 112.84%
Dec 31, 2010 -45.49%
Oct 3, 2010 -974.79%
Jul 4, 2010 -103.84%
Apr 4, 2010 315.11%
Dec 31, 2009 -1,365.44%
Sep 27, 2009 97.70%
Jun 28, 2009 4.85%